Clearside Biomedical to Report Fourth Quarter and Full Year 2024 Financial Results and Provide Corporate Update on Thursday, March 27, 2025

Rhea-AI Summary

Clearside Biomedical (Nasdaq: CLSD), a biopharmaceutical company focused on delivering therapies to the back of the eye through the suprachoroidal space (SCS®), has scheduled its fourth quarter and full year 2024 financial results announcement for Thursday, March 27, 2025 after market close.

The company will host a webcast and conference call at 4:30 p.m. Eastern Time to discuss the results and provide a corporate update. Investors can access the live call by dialing 888-506-0062 (domestic) or 973-528-0011 (international) with conference code 733956. The webcast will be available on Clearside's website under the Investors section: Events and Presentations.

ALPHARETTA, Ga., March 12, 2025 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD) (“Clearside” or the “Company”), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS^®), announced today that its fourth quarter and full year 2024 financial results will be reported on Thursday, March 27, 2025 after the close of the financial markets. Management will host a webcast and conference call at 4:30 p.m. Eastern Time to discuss the results and provide a corporate update.

The live and archived webcast may be accessed on the Clearside website under the Investors section: Events and Presentations. The live call can be accessed by dialing 888-506-0062 (domestic) or 973-528-0011 (international) and entering conference code: 733956. The Company suggests participants join 15 minutes in advance of the event.

About Clearside Biomedical, Inc.

Clearside Biomedical, Inc. is a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS^®) to improve patient outcomes. Clearside’s SCS injection platform, utilizing the Company’s patented SCS Microinjector^®, enables an in-office, repeatable, non-surgical procedure for the targeted and compartmentalized delivery of a wide variety of therapies to the macula, retina, or choroid to potentially preserve and improve vision in patients with sight-threatening eye diseases. Clearside is developing its own pipeline of small molecule product candidates for administration via its SCS Microinjector. The Company’s lead program, CLS-AX (axitinib injectable suspension), is in development for the treatment of neovascular age-related macular degeneration (wet AMD). Planning for a Phase 3 program is underway. In addition, Clearside is evaluating various small molecules for the potential long-acting treatment of geographic atrophy (GA). Clearside developed and gained approval for its first product, XIPERE^® (triamcinolone acetonide injectable suspension) for suprachoroidal use, which is available in the U.S. through a commercial partner. Clearside also strategically partners its SCS injection platform with companies utilizing other ophthalmic therapeutic innovations. For more information, please visit clearsidebio.com or follow us on LinkedIn and X.

Source: Clearside Biomedical, Inc.

Investor and Media Contacts:

Jenny Kobin
Remy Bernarda
ir@clearsidebio.com

FAQ

When will Clearside Biomedical (CLSD) release its Q4 and full year 2024 earnings?

Clearside Biomedical will release its Q4 and full year 2024 earnings on Thursday, March 27, 2025, after market close.

How can investors join Clearside Biomedical's Q4 2024 earnings call?

Investors can join by dialing 888-506-0062 (domestic) or 973-528-0011 (international) with code 733956, or access the webcast through Clearside's website Investors section.

What time is Clearside Biomedical's (CLSD) Q4 2024 earnings call?

The earnings call and webcast will begin at 4:30 p.m. Eastern Time on March 27, 2025.

Where can I find the webcast for CLSD's Q4 2024 earnings call?

The webcast can be accessed through Clearside's website under the Investors section: Events and Presentations.